Research tagged [pediatrics]

Optimal Sequencing of Immunotherapy for Pediatric B-Cell Acute Lymphoblastic Leukemia with Second Relapse Post-Allogeneic Hematopoietic Stem Cell Transplantation: A Clinical Consensus

Pediatric B-cell acute lymphoblastic leukemia (B-ALL) with second relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents a highly challenging clinical scenario with limited curative options. This paper synthesizes expert clinical opinion regarding the optimal sequencing and selection of novel immunotherapies, specifically tisagenlecleucel (CAR-T cell therapy) and blinatumomab (CD19/CD3 bispecific T-cell engager), for a 6-year-old female presenting with a second marrow relapse 14 months post-transplant. The discussion addresses critical considerations including blast burden management, manufacturing timelines, and potential toxicities in a heavily pre-treated patient. A consensus emerged favoring a strategy of bridging with blinatumomab to reduce blast burden, followed by definitive tisagenlecleucel. This approach leverages the immediate availability and debulking potential of blinatumomab to optimize conditions for CAR-T cell therapy, which offers superior long-term remission rates. The paper also explores the role of inotuzumab ozogamicin and discusses logistical challenges in diverse healthcare settings. This synthesis provides practical guidance for clinicians navigating complex treatment decisions in this ultra-high-risk patient population, emphasizing evidence-based sequencing to maximize therapeutic efficacy and minimize adverse events.